Drug Trial Radar · NCT00790673
A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1
Last checked: Nov 19, 2026Latest source record: Apr 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jul 2009
Primary completion
Jun 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- Can-Fite BioPharmaIndustry
- Sponsor type
- Industry
- First posted
- Nov 13, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will test the hypothesis that CF102 can safely and effectively suppress viral load in patients with chronic hepatitis C and high circulating levels of virus. The trial will monitor the safety of twice-daily oral dosing with CF102 over a 16-week period; will measure changes in viral load during therapy; and will measure blood concentrations of CF102 at various time points during dosing.
Conditions
- Chronic Hepatitis C
Interventions
CF 102Drug
Oral capsules
PlaceboDrug
Matching placebo capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Event Profile of Repeated Dosing of CF102Time frame: 16 weeks
- Effect of Viral LoadTime frame: 16 weeks
- Pharmacokinetic Behavior of CF102 During Repeated DosingTime frame: 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rabin Medical Center
Tel Aviv, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.